CN117883543A - Traditional Chinese medicine composition, preparation and application thereof - Google Patents
Traditional Chinese medicine composition, preparation and application thereof Download PDFInfo
- Publication number
- CN117883543A CN117883543A CN202410077242.4A CN202410077242A CN117883543A CN 117883543 A CN117883543 A CN 117883543A CN 202410077242 A CN202410077242 A CN 202410077242A CN 117883543 A CN117883543 A CN 117883543A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- donkey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 134
- 239000000203 mixture Substances 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 206010069351 acute lung injury Diseases 0.000 claims abstract description 39
- 108010010803 Gelatin Proteins 0.000 claims abstract description 38
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 38
- 229920000159 gelatin Polymers 0.000 claims abstract description 38
- 239000008273 gelatin Substances 0.000 claims abstract description 38
- 235000019322 gelatine Nutrition 0.000 claims abstract description 38
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 38
- 235000008434 ginseng Nutrition 0.000 claims abstract description 38
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 37
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 37
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 36
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 35
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 35
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 35
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 35
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 35
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 35
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 35
- 235000008397 ginger Nutrition 0.000 claims abstract description 35
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 35
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 34
- 241000405414 Rehmannia Species 0.000 claims abstract description 34
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 31
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 30
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 30
- 235000009120 camo Nutrition 0.000 claims abstract description 30
- 235000005607 chanvre indien Nutrition 0.000 claims abstract description 30
- 239000011487 hemp Substances 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract 9
- 241000234314 Zingiber Species 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 19
- 241000208340 Araliaceae Species 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 244000273928 Zingiber officinale Species 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 244000248557 Ophiopogon japonicus Species 0.000 description 30
- 240000004371 Panax ginseng Species 0.000 description 29
- 210000004072 lung Anatomy 0.000 description 29
- 239000000463 material Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 208000000059 Dyspnea Diseases 0.000 description 20
- 206010013975 Dyspnoeas Diseases 0.000 description 20
- 229960003957 dexamethasone Drugs 0.000 description 20
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 230000002757 inflammatory effect Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 206010021143 Hypoxia Diseases 0.000 description 12
- 102000003777 Interleukin-1 beta Human genes 0.000 description 12
- 108090000193 Interleukin-1 beta Proteins 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 230000007954 hypoxia Effects 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 7
- 208000004852 Lung Injury Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010069363 Traumatic lung injury Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 231100000515 lung injury Toxicity 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 238000002791 soaking Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000218236 Cannabis Species 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- 108050003558 Interleukin-17 Proteins 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000004704 glottis Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000003456 pulmonary alveoli Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 238000002640 oxygen therapy Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 241000212941 Glehnia Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241000207844 Scrophulariaceae Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- -1 ester polysaccharide Chemical class 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000010748 inability to lie flat Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019590 thick flavour Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating acute lung injury, which is prepared from the following raw materials in parts by weight: 2-10 parts of honey-fried licorice root, 3-10 parts of ginger, 3-10 parts of ginseng, 10-40 parts of dried rehmannia root, 3-10 parts of cassia twig, 3-10 parts of donkey-hide gelatin, 5-20 parts of dwarf lilyturf tuber, 5-20 parts of hemp seed and 5-30 parts of Chinese date. The invention also provides a traditional Chinese medicine compound preparation for treating acute lung injury and application thereof.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating acute lung injury, a preparation and application thereof.
Background
Acute Lung Injury (ALI), a severe inflammatory response of the lung, is usually triggered by severe infection, trauma or other serious disease.
There is currently no specific therapeutic drug directed against ALI itself. Most therapeutic strategies focus on supportive care such as oxygen therapy, mechanical ventilation, fluid management, elimination of underlying etiology, and the like. The traditional Chinese medicine has great advantages in the aspects of helping ALI improve clinical symptoms, delaying pathological progress, improving life quality and the like. In traditional Chinese medicine, ALI belongs to the categories of asthma, chest stuffiness, asthma and the like, and the pathogenesis of ALI is that excessive pathogenic factors gradually hurt vital qi of a human body, the vital qi of the human body is insufficient, excessive pathogenic factors are deficient, and finally deficiency of both qi, blood, yin and yang and the like are caused to collapse the human body.
Based on the prescription of classical medical books and long-term practical experience, the traditional Chinese medicine composition is prepared by selecting traditional Chinese medicine materials with specific pharmacological effects. The comprehensive treatment of traditional Chinese medicine and modern medicine based on the guidance of the traditional Chinese medicine syndrome differentiation theory is an important direction of ALI control, and the traditional Chinese medicine is easy to obtain and low in price, so that the traditional Chinese medicine is very suitable for popularization to the masses. Therefore, the research on the traditional Chinese medicine formula capable of preventing and treating ALI has important practical significance.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating acute lung injury, a preparation and application thereof.
The first aspect of the invention provides a traditional Chinese medicine composition for treating acute lung injury, which is prepared from the following raw materials in parts by weight: 2-10 parts of honey-fried licorice root, 3-10 parts of ginger, 3-10 parts of ginseng, 10-40 parts of dried rehmannia root, 3-10 parts of cassia twig, 3-10 parts of donkey-hide gelatin, 5-20 parts of dwarf lilyturf tuber, 5-20 parts of hemp seed and 5-30 parts of Chinese date.
In a preferred embodiment, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 3-9 parts of honey-fried licorice root, 4-8 parts of ginger, 3-8 parts of ginseng, 10-35 parts of dried rehmannia root, 4-9 parts of cassia twig, 4-9 parts of donkey-hide gelatin, 6-12 parts of dwarf lilyturf tuber, 6-15 parts of hemp seed and 6-15 parts of Chinese date.
In a preferred embodiment, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 2 parts of honey-fried licorice root, 3 parts of ginger, 3 parts of ginseng, 10 parts of dried rehmannia root, 3 parts of cassia twig, 3 parts of donkey-hide gelatin, 5 parts of dwarf lilyturf tuber, 5 parts of hemp seed and 5 parts of Chinese date.
In another preferred example, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 4 parts of honey-fried licorice root, 4 parts of ginger, 4 parts of ginseng, 15 parts of dried rehmannia root, 4 parts of cassia twig, 4 parts of donkey-hide gelatin, 7 parts of dwarf lilyturf tuber, 7 parts of hemp seed and 10 parts of Chinese date.
In another preferred example, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7 parts of honey-fried licorice root, 7 parts of ginger, 7 parts of ginseng, 27 parts of dried rehmannia root, 7 parts of cassia twig, 7 parts of donkey-hide gelatin, 14 parts of dwarf lilyturf tuber, 14 parts of hemp seed and 20 parts of Chinese date.
In another preferred example, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8 parts of honey-fried licorice root, 6 parts of ginger, 4 parts of ginseng, 15 parts of dried rehmannia root, 6 parts of cassia twig, 4 parts of donkey-hide gelatin, 12 parts of dwarf lilyturf tuber, 15 parts of hemp seed and 12 parts of Chinese date.
In another preferred example, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 parts of honey-fried licorice root, 10 parts of ginger, 10 parts of ginseng, 40 parts of dried rehmannia root, 10 parts of cassia twig, 10 parts of donkey-hide gelatin, 20 parts of dwarf lilyturf tuber, 20 parts of hemp seed and 30 parts of Chinese date.
In another preferred example, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8 parts of honey-fried licorice root, 6 parts of ginger, 4 parts of ginseng, 32 parts of dried rehmannia root, 6 parts of cassia twig, 4 parts of donkey-hide gelatin, 16 parts of dwarf lilyturf tuber, 16 parts of hemp seed and 12 parts of Chinese date.
The second aspect of the invention provides a traditional Chinese medicine compound preparation for treating acute lung injury, which is decoction, granules, powder, capsules, tablets or oral liquid taking the traditional Chinese medicine composition as an active ingredient.
The invention also provides application of the traditional Chinese medicine composition in preparing medicines for treating acute lung injury.
Details of the various aspects of the invention will be described in detail in subsequent sections. The features, objects, and advantages of the invention will be apparent from the description, and from the claims.
Description of the drawings:
FIG. 1 shows that the Chinese medicinal composition reduces pathological damage of lung tissue of ALI mice
FIG. 2 shows the pathological scoring changes of the lung injury of the ALI mice by the Chinese medicinal composition
FIG. 3 shows that the Chinese medicinal composition reduces the mRNA expression of the ALI mouse lung tissue inflammatory factors IL-1 beta, IL-6, TNF-alpha and hypoxia inducible factor Hif-1 alpha
FIG. 4 shows that the Chinese medicinal composition reduces the protein expression of ALI mouse serum inflammatory factors IL-1 beta, IL-6, IL-17 and TNF-alpha
Detailed Description
The traditional Chinese medicine raw materials adopted in the preparation process of the pharmaceutical composition have the following sources: radix Glycyrrhizae Preparata is processed product of radix Glycyrrhizae, and is dry root and rhizome of Glycyrrhiza uralensis Glycyrrhiza uralensis Fisch. Glycyrrhiza uralensis Glycyrrhiza inflata bat. Or Glycyrrhiza glabra Glycyrrhiza glabra L. Fresh rhizome of ginger, ginger Zingiber officinale Rosc. Dried roots and rhizomes of ginseng, a plant of the Araliaceae family, panax ginseng c.a. mey. Fresh or dried root tuber of rehmannia Rehmannia glutinosa Libosch, a figwort family plant. Ramulus Cinnamomi, dried twig of Cinnamomum cassia Cinnamomum cassia presl. Donkey-hide gelatin is a solid gum prepared by decocting dried or fresh donkey hide of Equus asinus L. Dried root tuber of ophiopogon japonicus of liliaceae Ophiopogon japonicus (L.f) Ker-Gawl. Dried mature fruit of Cannabis sativa L. Dried mature fruit of jujube, jujube of the Rhamnaceae family. Based on years of clinical practice experience, the inventor considers that exogenous six-exogenous seven-element affection can be the causative factor of the disease, but the deficiency of healthy qi and the loss of qi, blood, yin and yang all the time through the disease. In traditional Chinese medicine, ALI belongs to the categories of asthma, chest stuffiness, asthma and the like, and the pathogenesis of ALI is that excessive pathogenic factors gradually hurt the vital qi of a human body, the vital qi of the human body is insufficient, and the excessive pathogenic factors cause deficiency of both qi and blood and yin and yang, and the pathogenic factors attack the human body. In terms of the theory of traditional Chinese medicine, the recipe has the effects of tonifying qi, nourishing yin and activating yang, and mainly aims at strengthening the body resistance, and healthy qi is stored in the body resistance, and pathogenic factors cannot be dried in the body resistance and internal qi storage in the Huangdi's internal menstruation. The traditional Chinese medicine composition disclosed by the invention contains nine traditional Chinese medicines. The honey-fried licorice root is a monarch drug for strengthening middle-jiao and replenishing qi. Ginseng and fructus Jujubae tonify heart and spleen, and mix with radix Glycyrrhizae Preparata to nourish qi and blood, nourish lung qi, moisten lung and stop cough. Donkey-hide gelatin, hemp seed and dwarf lilyturf tuber are good at nourishing yin and blood, and E-hide gelatin and dwarf lilyturf tuber are good at nourishing lung yin and moistening lung dryness. Donkey-hide gelatin, fructus cannabis, dwarf lilyturf tuber, ginseng and Chinese date are all ministerial drugs. Ramulus Cinnamomi and rhizoma Zingiberis recens can warm yang and replenish qi, promote qi and blood circulation, promote qi circulation, and nourish the thick flavor without greasy, and are adjuvant drugs. Sheng Di Huang, huo Ma ren, E jiao and Mai Dong are combined and have the meaning of "Jin Shuixiang Sheng". Therefore, the herbs are compatible and together receive the actions of tonifying lung qi, nourishing lung yin and activating lung yang.
The traditional Chinese medicine composition of the invention can be prepared and obtained according to a conventional method in the field, for example: soaking all the medicinal materials in water for 0.5-2 hours, and decocting with strong fire for boiling and then decocting with slow fire for half an hour; removing residues, collecting decoction, and mixing the decoction; the water adding amount is controlled to be 2-3 cm higher than the medicinal material surface in the preparation process.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. Any method and materials similar or equivalent to those described can be used in the methods of the present invention. The experimental procedures, which do not address the specific conditions in the examples below, are generally carried out under conventional conditions or under conditions recommended by the manufacturer.
The above-mentioned features of the invention, or of the embodiments, may be combined in any desired manner. All of the features disclosed in this patent specification may be combined with any combination of the features disclosed in this specification, and the various features disclosed in this specification may be substituted for any alternative feature serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, the disclosed features are merely general examples of equivalent or similar features.
The raw materials of honey-fried licorice root, ginger, ginseng, dried rehmannia root, cassia twig, donkey-hide gelatin, dwarf lilyturf tuber, hemp seed, chinese date and the like used in the invention all conform to the relevant regulations under each medicinal material item of a body part of Chinese pharmacopoeia 2020. Each medicinal material is processed by cleaning, cutting, processing, crushing and the like, and before feeding, each medicinal material substance accords with the name through identification, and the quality accords with the national pharmacopoeia standard (the specific medicinal material identification method is executed by referring to the pharmacopoeia standard).
The traditional Chinese medicine composition has the effects of tonifying qi, nourishing yin and activating yang, can effectively improve symptoms of lung injury, prevent exacerbation of lung injury, can prevent and treat acute lung injury, has definite curative effect, small side effect and low cost, is particularly suitable for being taken in epidemic seasons of respiratory viruses, and has popularization and application values.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedures, which do not address the specific conditions in the examples below, are generally carried out under conventional conditions or under conditions recommended by the manufacturer. All percentages, ratios, proportions, or parts are by weight unless otherwise indicated.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred methods and materials described herein are presented for illustrative purposes only.
The above-mentioned features of the invention, or of the embodiments, may be combined in any desired manner. All of the features disclosed in this patent specification may be combined with any combination of the features disclosed in this specification, and the various features disclosed in this specification may be substituted for any alternative feature serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, the disclosed features are merely general examples of equivalent or similar features.
Example 1: preparation of Chinese medicinal composition
Weighing 2g of honey-fried licorice root, 3g of ginger, 3g of ginseng, 10g of dried rehmannia root, 3g of cassia twig, 3g of donkey-hide gelatin, 5g of dwarf lilyturf tuber, 5g of fructus cannabis and 5g of Chinese date, soaking all the medicinal materials in water for 0.5 hour, and decocting all the medicinal materials together with strong fire for boiling with slow fire for half an hour; removing residues, collecting decoction, and mixing the decoction; the water adding amount is controlled to be 2-3 cm higher than the medicinal material surface in the preparation process.
Example 2: preparation of Chinese medicinal composition
Weighing 4g of honey-fried licorice root, 4g of ginger, 4g of ginseng, 15g of dried rehmannia root, 4g of cassia twig, 4g of donkey-hide gelatin, 7g of dwarf lilyturf tuber, 7g of fructus cannabis and 10g of Chinese date, soaking all the medicinal materials in water for 0.5 hour, and decocting the medicinal materials together with strong fire for boiling with slow fire for half an hour; removing residues, collecting decoction, and mixing the decoction; the water adding amount is controlled to be 2-3 cm higher than the medicinal material surface in the preparation process.
Example 3: preparation of Chinese medicinal composition
Weighing 7g of honey-fried licorice root, 7g of ginger, 7g of ginseng, 27g of dried rehmannia root, 7g of cassia twig, 7g of donkey-hide gelatin, 14g of dwarf lilyturf tuber, 14g of fructus cannabis and 20g of Chinese date, soaking all the medicinal materials in water for 1 hour, and decocting all the medicinal materials together with strong fire for boiling and then decocting with slow fire for half an hour; removing residues, collecting decoction, and mixing the decoction; the water adding amount is controlled to be 2-3 cm higher than the medicinal material surface in the preparation process.
Example 4: preparation of Chinese medicinal composition
Weighing 8g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 15g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber, 15g of hemp seed and 12g of Chinese date, soaking all the medicinal materials in water for 1 hour, and decocting all the medicinal materials together with strong fire for half an hour with slow fire after boiling; removing residues, collecting decoction, and mixing the decoction; the water adding amount is controlled to be 2-3 cm higher than the medicinal material surface in the preparation process.
Example 5: preparation of Chinese medicinal composition
Weighing 10g of honey-fried licorice root, 10g of ginger, 10g of ginseng, 40g of dried rehmannia root, 10g of cassia twig, 10g of donkey-hide gelatin, 20g of dwarf lilyturf tuber, 20g of fructus cannabis and 30g of Chinese date, soaking all the medicinal materials in water for 1 hour, and decocting all the medicinal materials together with strong fire for boiling and then decocting with slow fire for half an hour; removing residues, collecting decoction, and mixing the decoction; the water adding amount is controlled to be 2-3 cm higher than the medicinal material surface in the preparation process.
Example 6: preparation of Chinese medicinal composition
Weighing 8g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 32g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 16g of dwarf lilyturf tuber, 16g of hemp seed and 12g of Chinese date, soaking all the medicinal materials in water for 1.5 hours, and decocting the medicinal materials together with strong fire for boiling with slow fire for half an hour; removing residues, collecting decoction, and mixing the decoction; the water adding amount is controlled to be 2-3 cm higher than the medicinal material surface in the preparation process.
Example 7: pharmaceutical research of traditional Chinese medicine composition
7.1 animals:
60 healthy male C57BL/6 mice, SPF grade, body mass (20-22 g), shanghai Laek laboratory animal Limited, eligibility Co., elio: 20220004035589 special standard pellet feed, water fed, animal ethical examination number: pZSHUTCM2310260004, experiments were carried out in the laboratory animal center facility at Shanghai university (SYCK 2020-0009).
7.2 major equipment and instrumentation:
cryo-centrifuge 3K15 (Sigma, usa); microplate reader 680 (Bio-Rad, USA); real-time fluorescent quantitative PCR instrument (quantsudio 3, usa); PCR instrument (Mastercycler nexus, germany); SDS-PAGE electrophoresis apparatus (MINIProtean 2 Bio-Rad, USA); pathological microtome (Shanghai Leka instruments Co., ltd., china).
7.3 drugs and reagents:
dexamethasone tablets, tianjin Yijin pharmaceutical Co., ltd., lot number 501220321; ester polysaccharide, sigma-aldrich, lot 0000153963; IL-6ELISA kit (Nanjing Bo-Miao, cat# BY-EM 220188); IL-1 beta ELISA kit (Nanjing Bo-Miao, cat# BY-EM 220174); TNF-alpha ELISA kit (Nanjing Bo-Miao, cat# BY-EM 220852); IL-17ELISA kit (Nanjing Bo-Miao, cat# BY-EM 220170); hif-1 alpha ELISA kit (Yuan Xin Bio, cat# YX-E20354); RNA extraction kit (B0004D, EZBioscience, suzhou, china); reverse transcription kit (TakaRa, china, cat# RR 036A); qPCR kit (Northenan, china, cat# Q711-02); primer sequences (Biotechnology Co., ltd., china).
The Chinese medicinal composition prepared in example 4 was concentrated to 38.4ml by heating, cooling, and storing at 4deg.C.
7.4 statistical method:
all data were using SPSS29.0 statistical software. All experiments were repeated 3 times or more, data were obtainedAnd (3) representing. After the variance alignment test, more than two groups of data are subjected to single-factor variance analysis, and the difference between the two groups is subjected to independent sample t test. P <0.05 represents a statistical significance.
7.5 general status observations of mice:
the experimental method comprises the following steps:
healthy male SPF grade C57BL/6 mice were randomly divided into normal, model, traditional Chinese medicine composition (high, medium, low dose) and dexamethasone; each group of 10. The weight (20-22) g is fed into SPF-level barrier environment, the light and the darkness are alternated for 12 hours, (24+/-2) DEG C, the relative humidity is 55+/-5%, and drinking water is taken freely. After one week of adaptive feeding, the Chinese medicinal composition (high, medium and low doses) was administered with 0.2ml of the Chinese medicinal composition (high dose 21.32g/kg, medium dose 10.66g/kg, low dose 5.33 mg/kg) at the corresponding concentration, respectively, 1 time a day; dexamethasone groups were given 0.2ml dexamethasone for intragastric administration (5 mg/kg); normal group and model group perfuse stomach with physiological saline 0.2ml, 1 time daily. On day 7 of gastric lavage, mice were anesthetized, supine fixed on the console, throat and glottis exposed, slowly inserted into the airway with soft cannula of venous indwelling needle under bright field, and 50ul of LPS was added dropwise at 5mg/kg dose. LPS tracheae instillation molding was given to mice in model group, chinese medicinal composition (high, medium, low dose) group and dexamethasone group. The normal group was instilled with 50ul of normal saline trachea. All mice were observed for mental status, activity, coat gloss, death, etc. during the experiment. Mice were treated 24 hours after molding, and serum was collected and isolated for serological testing. The right lung leaf is fixed in 4% paraformaldehyde, dehydrated by gradient ethanol, embedded in paraffin, and sliced for lung tissue pathological morphology detection. The rest lung is quick frozen in liquid nitrogen and stored in a refrigerator at-80 ℃ for standby.
Experimental results:
during the experiment, 3 mice in the model group die, the model group shows transient dyspnea symptoms after the LPS is instilled into the trachea, and the symptoms of deficiency of both qi and yin gradually appear, so that the mice are well and calm, listlessness, slow reaction, obvious reduction of activity, reduced food intake, reduced water intake, dry and matt fur, hair loss and dry stool. Compared with mice in a model group, a traditional Chinese medicine composition group and a dexamethasone group, the mice in a normal group show good mental state, lively and active, quick response, normal eating and smooth fur. The traditional Chinese medicine composition group and dexamethasone group mice have small response to the molding drug LPS after being subjected to gastric lavage administration, and the symptoms of deficiency of both qi and yin are relieved to a certain extent.
7.6 observation of the inhibition of dyspnea in mice by the Chinese medicinal composition
The experimental method comprises the following steps:
two experimental technicians observe the dyspnea symptoms of the mice, smell and obviously dry and wet rally or phlegm and borborygmus under the condition of not using a stethoscope, record the attack time, and take the average value of the recorded values of the two persons.
Experimental results:
table 1 shows the inhibition of the dyspnea in mice by the Chinese medicinal composition; dyspnea occurred in all mice in the model group. Compared with the model group, the high, medium and low dose groups of the traditional Chinese medicine composition have obviously reduced dyspnea time (P < 0.01), and the high dose group has no obvious difference from the dexamethasone group (P > 0.05). The traditional Chinese medicine composition is proved to relieve dyspnea symptoms, and the degree of relief of a high-dose group is similar to that of dexamethasone as a western medicine.
Table 1 comparison of dyspnea onset time in groups of mice
Note that: comparison to model group, represent: p <0.05, represents: p <0.01; comparison to the dexamethasone group: delta represents: p <0.05, Δ represents: p <0.01
7.7 pulmonary tissue pathological morphology observations in mice
The experimental method comprises the following steps:
fresh lung tissue of mice was taken and fixed with 4% paraformaldehyde. Paraffin sections were routinely dehydrated, procedure: 75% ethanol 2h, 85% ethanol 2h, 90% ethanol 2h, 100% ethanol 45min, ethanol+xylene (1:1) 10min, xylene 8min, paraffin 1h. Paraffin is conventionally embedded. Placing the wax block on a freezing table at-20deg.C, cooling, clamping on a paraffin slicing machine seat, cutting into 4-6 micro-sections, placing the slices on the water surface (water temperature 40 deg.C) of a spreading machine, taking out tissue slices with a glass slide, and baking in a 60 deg.C oven for 1 hr. Paraffin sections were dewaxed to water, procedure: xylene I20 min, xylene II 20min, absolute ethanol I5 min, absolute ethanol II 5min, 75% ethanol 5min, gradient dewaxing and water washing. The slices are stained with hematoxylin for 3-5min, the excess dye liquor is washed by tap water, 1% hydrochloric acid aqueous solution is differentiated for a few seconds, the tap water is rinsed, then 0.6% -0.7% ammonia aqueous solution returns to blue, and the tap water is rinsed for a few seconds. Paraffin section gradient alcohol (85% ethanol to 95% ethanol) is dehydrated and put into eosin dye solution for dyeing for 5min. The paraffin wax slice is sequentially put into absolute ethyl alcohol I for 5min, absolute ethyl alcohol II for 5min, absolute ethyl alcohol III for 5min, n-butyl alcohol for 5min, dimethylbenzene I for 5min and dimethylbenzene II for 5min to be transparent, and the slice is taken out of dimethylbenzene to be dried slightly, and is sealed by neutral resin. Sections were observed under an optical microscope and pictures were saved.
Experimental results:
HE staining observations of mouse lung tissue
FIG. 1 shows the effect of a Chinese medicinal composition on the pathological morphology of the lung tissue of ALI mice; as can be seen from fig. 1, the lung tissue of the normal group has clear alveolar structure, uniform alveolar size and complete airway mucosa epithelium structure, and no obvious pathological change is seen; the lung tissue structure of the mice in the model group is disordered, a large number of red blood cells can be seen in the alveolus space and the interstitium, sheet-shaped blood foci can be seen with naked eyes, the alveolus wall is obviously thickened, the transparent film of the alveolus wall is formed, and part of epithelial cells of bronchi fall off and are infiltrated by neutrophils and lymphocytes. The pathological changes of each group of the traditional Chinese medicine composition are relieved.
7.8 mice lung tissue injury pathology score
The experimental method comprises the following steps:
scoring the lung tissue sections, wherein the scoring standard is respectively 0 to 4 points according to the degrees of lung localized necrosis, neutrophil erythrocyte exudation, alveolar space thickening, alveolar space enlargement and lung hyaline membrane formation: the non-damage is 0 point, the lesion range is less than 25 percent and is 1 point, and the lesion range is 25 percent to 50 percent and is 2 points; the pathological change range is 51-75% of 3 minutes, and the pathological change range is more than 75% of 4 minutes. 10 high power fields per slice were scored.
Experimental results:
FIG. 2 shows the pathological scoring changes of the lung injury of ALI mice by the traditional Chinese medicine composition; in the figure, # compared to the normal group: p <0.05, #: p <0.01; comparison to model group,: p <0.05,: p <0.01; comparison to the dexamethasone group: delta: p <0.05, Δ: p <0.01; as can be seen from fig. 2, the lung injury pathology score was significantly increased in the mice in the model group compared to the normal group (P < 0.01). Compared with the model group, the lung injury score of the mice in the high, medium and low dose groups of the traditional Chinese medicine composition is obviously reduced (P < 0.01), and the lung injury score of the mice in the high dose group is not obviously different from that of the dexamethasone group (P > 0.05). The traditional Chinese medicine composition is proved to lighten the lung pathological injury of mice, and the degree of lightening of a high-dose group is similar to that of dexamethasone as a western medicine.
7.9 determination of expression of inflammatory factors IL-1 beta, IL-6, TNF-alpha and hypoxia inducible factor Hif-1 alpha mRNA in mouse lung tissue
The experimental method comprises the following steps:
RNA was extracted from fresh lung tissue using RNA extraction kit. And then reverse transcribed into cDNA. The primer sequences are shown in Table 2. Using Quantum studio TM Real-time quantitative PCR was performed in line 3. Analyzing data by relative quantification method with GAPDH as reference, 2 -△△Ct The relative expression level of mRNA was measured.
TABLE 2 primer sequences
Experimental results:
FIG. 3 shows the mRNA expression of the lung tissue inflammatory factors IL-1 beta, IL-6, TNF-alpha and hypoxia inducible factor Hif-1 alpha of ALI mice by the Chinese medicinal composition; in the figure, # compared to the normal group: p <0.05, #: p <0.01; comparison to model group,: p <0.05,: p <0.01; comparison to the dexamethasone group: delta: p <0.05, Δ: p <0.01; as can be seen from FIG. 3, IL-1β, IL-6, TNF- α, hif-1α mRNA expression was significantly elevated in lung tissue of mice in the model group (P < 0.05) compared to the normal group. Compared with the model group, the expression of IL-1 beta, IL-6, TNF-alpha and Hif-1 alpha mRNA in lung tissues of mice in high, medium and low dose groups of the traditional Chinese medicine composition is obviously reduced (P <0.05 and P < 0.01). The high dose group showed no significant difference in IL-6 and TNF-. Alpha.mRNA expression levels from the dexamethasone group (P > 0.05). The traditional Chinese medicine composition is proved to obviously lighten the gene expression of the inflammatory factors and the hypoxia-inducible factors of the lung tissues of the mice, and partial indexes are similar to those of dexamethasone western medicine.
7.10 determination of the expression of inflammatory factors IL-1 beta, IL-6, IL-17, TNF-alpha protein in mouse serum
The experimental method comprises the following steps:
mouse serum was taken and assayed for IL-1 beta, IL-6, IL-17, TNF-alpha levels according to the instructions of the ELISA kit. The standard and sample were added separately to the pre-embedded enzyme plates. The respective biotin antigen was added and incubated at 37℃for 30 minutes. After addition of the developer and terminator, the OD value of each well was measured at an absorbance of 450nm using an enzyme-labeled instrument. And (5) establishing a linear regression equation according to the standard substance concentration and the OD value thereof, and calculating the sample concentration.
Experimental results:
FIG. 4 shows the protein expression of the Chinese medicinal composition on serum IL-1 beta, IL-6, IL-17 and TNF-alpha of ALI mice; in the figure, # compared to the normal group: p <0.05, #: p <0.01; comparison to model group,: p <0.05,: p <0.01; comparison to the dexamethasone group: delta: p <0.05, Δ: p <0.01; as can be seen from FIG. 4, IL-1 beta, IL-6, IL-17, TNF-alpha protein expression was significantly elevated in the serum of mice from the model group compared to the normal group (P < 0.01). Compared with the model group, the IL-1 beta protein expression in the serum of the mice in the high, medium and low dose groups of the traditional Chinese medicine composition is obviously reduced (P <0.05, P < 0.01). The IL-1 beta protein expression in the serum of the mice in the high, medium and low dose groups of the traditional Chinese medicine composition is obviously reduced (P <0.05, P < 0.01), and the IL-6, IL-17 and TNF-alpha protein expression in the serum of the mice in the high, medium dose groups of the traditional Chinese medicine composition is obviously reduced (P <0.05, P < 0.01). Compared with the dexamethasone group, the partial index has no obvious difference (P > 0.05) with the dexamethasone group. The traditional Chinese medicine composition is proved to reduce the level of inflammatory factors in serum of mice, and the reduction degree of partial indexes is similar to that of dexamethasone western medicine. EXAMPLE 8 comparative study of Chinese medicinal composition and literature formula
Experimental animals:
32 healthy male C57BL/6 mice, SPF grade, body mass (20-22 g), shanghai Laek laboratory animal Limited, eligibility Co., elio: 20220004035589 special standard pellet feed, water fed, animal ethical examination number: pZSHUTCM2310260004, experiments were carried out in the laboratory animal center facility at Shanghai university (SYCK 2020-0009).
Experimental drugs:
the Chinese medicinal composition was prepared as in example 4
The literature formula is as follows:
30g of honey-fried licorice root, 9g of dried ginger, 15g of ginseng, 15g of prepared rehmannia root, 15g of cassia twig, 9g of donkey-hide gelatin (melted), 15g of dwarf lilyturf tuber, 9g of hemp seed, 9g of Chinese date, 15g of glehnia root, 12g of leech and 12g of arisaema cum bile. Decocting in cold water, and collecting 300ml juice. Reference (Zhang Yangyang, sun, yang Xing, etc.) modified decoction of radix Glycyrrhizae Preparata in combination with enalapril for treating chronic obstructive pulmonary disease complicated with heart failure has been studied [ J ]. Shanxi Chinese medicine, 2021,42 (09): 1219-1222.).
The experimental method comprises the following steps:
mice were randomly divided into normal, model, traditional Chinese medicine composition and literature. 8 in each group. After one week of adaptive feeding, the traditional Chinese medicine composition group and the literature formula are respectively administered with the traditional Chinese medicine composition and the literature formula for stomach irrigation 1 time a day; normal group and model group perfuse the stomach with equal volume of physiological saline, 1 time a day. On day 7 of gastric lavage, mice were anesthetized, supine fixed on the console, throat and glottis exposed, slowly inserted into the airway with soft cannula of venous indwelling needle under bright field, and 50ul of LPS was added dropwise at 5mg/kg dose. The mice in the model group, the traditional Chinese medicine composition group and the literature group are subjected to LPS trachea instillation molding. The normal group was instilled with 50ul of normal saline trachea. All mice were observed for dyspnea symptoms during the experiment and the time of onset was recorded. Mice were treated 24 hours after molding, serum was collected and isolated for serological testing, and IL-1β, IL-6, hif-1α levels were tested according to the instructions of ELISA kit.
The statistical method comprises the following steps:
all data were using SPSS29.0 statistical software. Data toAnd (3) representing. After the variance alignment test, a one-factor analysis of variance was used for more than two sets of data. P <0.05 represents a statistical significance.
Experimental results:
table 3 shows that the inhibition effect of the traditional Chinese medicine composition on the dyspnea of mice is superior to that of the literature formula; dyspnea occurred in all mice in the model group. As can be seen from table 3, compared with the model group, the group of the traditional Chinese medicine composition has significantly reduced dyspnea time (P < 0.01), and has better effect of inhibiting dyspnea than the literature group (P < 0.01).
Table 3 comparison of dyspnea onset time in groups of mice
Note that: comparison to model group, represent: p <0.05, represents: p <0.01; comparison with literature: delta represents: p <0.05, Δ represents: p <0.01
Table 4 shows the effect of the Chinese medicinal composition on inflammatory factors and hypoxia inducible factors of mice; as can be seen from Table 4, the inflammatory factors IL-1β, IL-6 and hypoxia inducible factor Hif-1α expression were significantly elevated in the model group compared to the normal group (P < 0.01). The inhibiting effect of the traditional Chinese medicine composition group on the expression of the inflammatory factors and the hypoxia inducible factors of the mice is superior to that of a literature formula group (P < 0.01).
TABLE 4 level of inflammatory and hypoxia inducible factors in mouse serumpg/ml)
Note that: in comparison with the normal group, # represents: p <0.05, # # denotes: p <0.01; comparison to model group, represent: p <0.05, represents: p <0.01; comparison with literature: delta represents: p <0.05, Δ represents: p <0.01
EXAMPLE 9 comparative study of Chinese medicinal composition and Detachable prescription
Experimental animals:
96 healthy male C57BL/6 mice, SPF grade, body mass (20-22 g), shanghai Laek laboratory animal Limited, eligibility Co., ltd., elio-gram: 20220004035589 special standard pellet feed, water fed, animal ethical examination number: pZSHUTCM2310260004, experiments were carried out in the laboratory animal center facility at Shanghai university (SYCK 2020-0009). Experimental drugs:
the Chinese medicinal composition was prepared as in example 4
Medicine composition of formula 1: 6g of ginger, 4g of ginseng, 15g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber, 15g of hemp seed and 12g of Chinese date, and the medicine composition of the prescription 2 comprises the following components: 8g of honey-fried licorice root, 4g of ginseng, 15g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber, 15g of hemp seed, 12g of Chinese date and 3 medicaments of formula 3: 8g of honey-fried licorice root, 6g of ginger, 15g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber, 15g of hemp seed and 12g of Chinese date.
Medicine composition of formula 4: 8g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 6g of cassia twig, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber, 15g of hemp seed, 12g of Chinese date and 5 medicaments of formula of disassembly: 8g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 15g of dried rehmannia root, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber, 15g of hemp seed, 12g of Chinese date and 6 split prescription: 8g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 15g of dried rehmannia root, 6g of cassia twig, 12g of dwarf lilyturf tuber, 15g of hemp seed, 12g of Chinese date and 7 medicaments of formula of disassembly: 8g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 15g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 15g of hemp seed, 12g of Chinese date and 8 medicaments of formula 8: 8g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 15g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber, 12g of Chinese date and 9 split prescription: 8g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 15g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber and 15g of hemp seed
The preparation method of the medicine comprises the following steps: obtained by the method of example 4.
The experimental method comprises the following steps:
the mice were randomly divided into normal group, model group, chinese medicinal composition group and split group (split 1, split 2, split 3, split 4, split 5, split 6, split 7, split 8, split 9). 8 in each group. After one week of adaptive feeding, the traditional Chinese medicine composition and the prescription are respectively administered for 1 time a day; normal group and model group perfuse the stomach with equal volume of physiological saline, 1 time a day. On day 7 of gastric lavage, mice were anesthetized, supine fixed on the console, throat and glottis exposed, slowly inserted into the airway with soft cannula of venous indwelling needle under bright field, and 50ul of LPS was added dropwise at 5mg/kg dose. The model group, the traditional Chinese medicine composition group and the prescription-dismantling group mice are subjected to LPS trachea instillation molding. The normal group was instilled with 50ul of normal saline trachea. All mice were observed for dyspnea symptoms during the experiment and the time of onset was recorded. Mice were treated 24 hours after molding, and serum was collected and isolated for serological testing.
The statistical method comprises the following steps:
all data were using SPSS29.0 statistical software. Data toAnd (3) representing. After the variance alignment test, a one-factor analysis of variance was used for more than two sets of data. P <0.05 represents a statistical significance.
Experimental results:
table 5 shows that the inhibition effect of the traditional Chinese medicine composition on the dyspnea symptoms of mice, inflammatory factors and hypoxia inducible factors is superior to that of all the prescription groups; dyspnea occurred in all mice in the model group. As can be seen from table 5, compared with the model group, the time of inhalation of the traditional Chinese medicine composition and each prescription is significantly reduced (P < 0.01), but the treatment effect of each prescription of any least one medicine is inferior to that of the traditional Chinese medicine composition, and the traditional Chinese medicine composition and each prescription have statistical difference (P < 0.01). Compared with the normal group, the serum inflammatory factor IL-6 and hypoxia inducible factor Hif-1 alpha of the mice in the model group are obviously increased (P < 0.01). Compared with the model group, the inflammatory factor IL-6 and hypoxia inducible factor Hif-1 alpha in serum of the traditional Chinese medicine composition and each prescription are obviously reduced (P < 0.01), but the treatment effect of each prescription of any least one medicine is not as good as that of the traditional Chinese medicine composition, and the traditional Chinese medicine composition has statistical difference (P < 0.01).
Table 5 comparison of dyspnea onset time, inflammatory factors, and hypoxia inducible factors in mice of each group/>
Note that: in comparison with the normal group, # represents: p <0.05, # # denotes: p <0.01; comparison to model group, represent: p <0.05, represents: p <0.01;
EXAMPLE 10 comparative study of traditional Chinese medicine composition treatment and conventional treatment by Western medicine alone
Study object
The doctor is in the doctor's outpatient department of traditional Chinese medicine in the eosin hospital, the doctor confirms that the doctor is in the recovery period as acute lung injury, and the doctor is in the patient with deficiency of both qi and yin in the traditional Chinese medicine dialectical mode.
Western diagnostic criteria:
diagnostic criteria for Acute Lung Injury (ALI) were defined by berlin in 2012 (Acute respiratory distress syndrome: the Berlin Definition): with changes in pulmonary imaging, paO2/FiO2 is less than or equal to 300mmHg, and pulmonary edema caused by heart failure and fluid overload is excluded. The onset time is within about 1 month.
Diagnostic criteria for traditional Chinese medicine:
refer to the section "wheeze syndrome" of "national advanced Chinese medicine university planning teaching material traditional Chinese medicine science (tenth edition). The main clinical manifestations include dyspnea, hypodynamia, open mouth and shoulder, stir-frying of nose wings, inability to lie flat, lassitude, spontaneous perspiration or night sweat, low fever, feverish sensation in palms and soles, anorexia, dry mouth and tongue, and dark-red tongue with little coating. Inclusion criteria: (1) the age of 18 years is less than or equal to 80 years; (2) meets the Western medicine and Chinese medicine diagnosis standards; (3) The patient himself and herself and the family members agree and are willing to sign informed consent.
Exclusion criteria:
(1) Patients with non-recovery period and critical illness. (2) Patients with heart failure and severe liver and kidney dysfunction are combined with serious other system diseases. (3) patients with mental disorder and mental diseases. (4) allergic constitution.
The research method comprises the following steps:
in the recovery period of acute lung injury, the Chinese medicine is a patient with deficiency of both qi and yin. A total of 60 cases are randomly divided into a traditional Chinese medicine group and a control group, and 30 cases are in each group. Western medicine general treatment of acute lung injury refers to the guidelines for diagnosis and treatment of acute lung injury/acute respiratory distress syndrome (2006). The control group was treated with western medicine conventional treatments (including oxygen therapy, antibiotics, glucocorticoids, fluid management, etc.). The traditional Chinese medicine composition is added with traditional Chinese medicine composition (8 g of honey-fried licorice root, 6g of ginger, 4g of ginseng, 15g of dried rehmannia root, 6g of cassia twig, 4g of donkey-hide gelatin, 12g of dwarf lilyturf tuber, 15g of fructus cannabis and 12g of Chinese date) on the basis of conventional treatment of Western medicine, and the preparation method is the same as that of example 4, 1 dose per day, and 1 course of treatment is taken after meals for 7 days. The effect was observed after treatment 7.
Standard of efficacy:
the scores before and after the administration of the patients are recorded by referring to the traditional Chinese medicine syndrome scoring scale of the clinical disease diagnosis according to cure improvement standard and the traditional Chinese medicine new medicine clinical research guiding principle. The calculation formula is as follows: treatment efficiency = (total integration before treatment-total integration after treatment)/total integration before treatment x 100. And (3) healing: the patient has no obvious movement and is asthmatic, debilitating and has an oxygenation index of more than 300mHg; the integral reduction of the symptoms of the traditional Chinese medicine is more than or equal to 90 percent; the effect is shown: the patient is only slightly shorted of breath and has no obvious hypodynamia; the integral of the traditional Chinese medicine symptoms is reduced by less than 90 percent and more than 60 percent; progress: the asthma of the patient is relieved before movement, but partial symptoms still exist, and the integral of the symptoms of the traditional Chinese medicine is reduced by less than 60 percent; invalidation: the shortness of breath and the wheeze of patients are generally not obvious as before, speaking is often interrupted or the wheeze is obvious, and the symptoms such as listlessness, general debilitation, dry mouth and tongue, spontaneous perspiration and night sweat are still remained; the integral of the symptoms of the traditional Chinese medicine is reduced by less than 30 percent. Total effective rate = recovery rate + significant efficiency + progress rate.
And (3) observing inflammation indexes:
the neutrophil ratio (NEUT%), C-reactive protein (CRP) in the blood was measured for 7d of treatment in both groups of patients. Safety monitoring:
and observing whether the patient has adverse reactions such as anaphylactic reaction, diarrhea, vomit and dizziness.
Statistical analysis:
all data were processed using SPSS29.0 statistical software. Metering data toAnd (3) representing. After the homogeneity test of variance, the comparison between the groups before and after treatment adopts an independent sample t test, and the comparison in the same group adopts single factor variance analysis. The count data is expressed as an example (%), and Pearson χ is used as the classification count data 2 The assay was performed. P (P)<0.05 is a significant difference with statistical significanceMeaning.
Study results:
general data of patients were collected, age, sex, smoking history, no obvious differences, and the two groups of patients were comparable. Table 6 shows the efficacy of the Chinese medicinal composition on acute lung injury. The total effective rate of the traditional Chinese medicine group can reach 96.7%, the curative effect of the traditional Chinese medicine group is superior to that of a control group, and the difference has statistical significance (P < 0.01). The traditional Chinese medicine composition is proved to obviously relieve the symptoms of patients, and the total effective rate of the traditional Chinese medicine composition is superior to that of the traditional Chinese medicine composition for treatment by combination with the traditional Chinese medicine composition. Table 7 shows the effect of the Chinese medicinal composition on the inflammatory index of patients with acute lung injury. Compared with the control group, the neutrophil ratio and C-reactive protein of the traditional Chinese medicine group patients are obviously reduced (P < 0.01). The traditional Chinese medicine composition can reduce inflammation of patients. Through safety monitoring, adverse reactions do not occur to patients in the traditional Chinese medicine group. The traditional Chinese medicine composition has good safety and definite clinical curative effect, and has important clinical value on acute lung injury.
Table 6 comparison of efficacy of Chinese medicinal composition on acute lung injury
TABLE 7 comparison of inflammation index for two groups of patients
Note that: in comparison to pre-treatment, # represents: p <0.05, # # denotes: p <0.01; comparison to control post-treatment, represent: p <0.05, represents: p <0.01;
the various aspects of the invention have been described above. It will be understood, however, that equivalent changes and modifications may be made thereto by those skilled in the art without departing from the spirit of the invention, which changes and modifications likewise fall within the scope of the appended claims.
Claims (10)
1. The traditional Chinese medicine composition for treating acute lung injury is characterized by being prepared from the following raw materials in parts by weight: 2-10 parts of honey-fried licorice root, 3-10 parts of ginger, 3-10 parts of ginseng, 10-40 parts of dried rehmannia root, 3-10 parts of cassia twig, 3-10 parts of donkey-hide gelatin, 5-20 parts of dwarf lilyturf tuber, 5-20 parts of hemp seed and 5-30 parts of Chinese date.
2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 3-9 parts of honey-fried licorice root, 4-8 parts of ginger, 3-8 parts of ginseng, 10-35 parts of dried rehmannia root, 4-9 parts of cassia twig, 4-9 parts of donkey-hide gelatin, 6-12 parts of dwarf lilyturf tuber, 6-15 parts of hemp seed and 6-15 parts of Chinese date.
3. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 2 parts of honey-fried licorice root, 3 parts of ginger, 3 parts of ginseng, 10 parts of dried rehmannia root, 3 parts of cassia twig, 3 parts of donkey-hide gelatin, 5 parts of dwarf lilyturf tuber, 5 parts of hemp seed and 5 parts of Chinese date.
4. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7 parts of honey-fried licorice root, 7 parts of ginger, 7 parts of ginseng, 27 parts of dried rehmannia root, 7 parts of cassia twig, 7 parts of donkey-hide gelatin, 14 parts of dwarf lilyturf tuber, 14 parts of hemp seed and 20 parts of Chinese date.
5. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 4 parts of honey-fried licorice root, 4 parts of ginger, 4 parts of ginseng, 15 parts of dried rehmannia root, 4 parts of cassia twig, 4 parts of donkey-hide gelatin, 7 parts of dwarf lilyturf tuber, 7 parts of hemp seed and 10 parts of Chinese date.
6. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8 parts of honey-fried licorice root, 6 parts of ginger, 4 parts of ginseng, 15 parts of dried rehmannia root, 6 parts of cassia twig, 4 parts of donkey-hide gelatin, 12 parts of dwarf lilyturf tuber, 15 parts of hemp seed and 12 parts of Chinese date.
7. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 parts of honey-fried licorice root, 10 parts of ginger, 10 parts of ginseng, 40 parts of dried rehmannia root, 10 parts of cassia twig, 10 parts of donkey-hide gelatin, 20 parts of dwarf lilyturf tuber, 20 parts of hemp seed and 30 parts of Chinese date.
8. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8 parts of honey-fried licorice root, 6 parts of ginger, 4 parts of ginseng, 32 parts of dried rehmannia root, 6 parts of cassia twig, 4 parts of donkey-hide gelatin, 16 parts of dwarf lilyturf tuber, 16 parts of hemp seed and 12 parts of Chinese date.
9. A Chinese medicinal compound preparation for treating acute lung injury is characterized in that the Chinese medicinal compound preparation is decoction, granules, powder, capsules, tablets or oral liquid taking the Chinese medicinal composition as an active ingredient in claim 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8.
10. Use of a Chinese medicinal composition according to claim 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 in the manufacture of a medicament for the treatment of acute lung injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410077242.4A CN117883543A (en) | 2024-01-18 | 2024-01-18 | Traditional Chinese medicine composition, preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410077242.4A CN117883543A (en) | 2024-01-18 | 2024-01-18 | Traditional Chinese medicine composition, preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117883543A true CN117883543A (en) | 2024-04-16 |
Family
ID=90644275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410077242.4A Pending CN117883543A (en) | 2024-01-18 | 2024-01-18 | Traditional Chinese medicine composition, preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117883543A (en) |
-
2024
- 2024-01-18 CN CN202410077242.4A patent/CN117883543A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103784933A (en) | Recurrent oral ulcer power | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN111437375A (en) | Medicine for treating asthma | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN105412281A (en) | Traditional Chinese medicinal composition for treating allergic asthma and preparation method thereof | |
| WO2024000914A1 (en) | Traditional chinese medicine composition for treating skin diseases and preparation method therefor | |
| CN117883543A (en) | Traditional Chinese medicine composition, preparation and application thereof | |
| CN112336802B (en) | Traditional Chinese medicine composition for improving glycolipidosis metabolism of diabetes and application thereof | |
| CN110327437B (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| CN109663100B (en) | Traditional Chinese medicine composition for treating optic neuritis and preparation method and application thereof | |
| CN112138084A (en) | Traditional Chinese medicine formula for treating bronchiectasis syndrome of qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN116098968B (en) | Traditional Chinese medicine composition for treating yang qi deficiency and defensive exterior insecurity asthma and application thereof | |
| CN105055981A (en) | Medicine for treating postpartum persistent lochia caused by blood stasis | |
| CN115845021B (en) | A Chinese medicinal composition for preventing and treating pulmonary fibrosis, and its preparation method | |
| CN108355124A (en) | A kind of Chinese medicine composition that treating Air way mucus hypersecretion and its application | |
| CN115025174B (en) | A Chinese medicinal composition for treating chronic obstructive pulmonary disease, and its preparation method | |
| CN115998818B (en) | New application of Dongtian vinca paste, pharmaceutical composition and application | |
| CN116509824B (en) | Traditional Chinese medicine gel and preparation process thereof | |
| CN114796419B (en) | Traditional Chinese medicine composition for treating acute pancreatitis and application thereof | |
| CN114748465B (en) | Pharmaceutical composition for treating infantile asthma and application thereof | |
| CN114209781B (en) | Traditional Chinese medicine composition for treating asthma | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN114259523B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating cough variant asthma | |
| CN110051720B (en) | A Chinese medicinal decoction containing lignum Dalbergiae Odoriferae and its application as medicine for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |